Heart Rate Variability in Pulmonary Arterial Hypertension

Area of Science:

• Cardiology
• Pulmonary Medicine
• Biomedical Engineering

Background:

• Resting heart rate is used in risk assessment for pulmonary arterial hypertension (PAH).
• Home-based heart rate variability (HRV) monitoring may offer early insights into physiological changes in PAH.
• The study explored HRV's potential as a treatment-responsive measure and outcome predictor in PAH.

Purpose of the Study:

• To investigate if 7-day continuous home-based HRV monitoring is a treatment-responsive measure in PAH.
• To determine if HRV monitoring is associated with clinical outcomes in PAH patients.
• To compare HRV and heart rate changes between stable PAH patients and those undergoing treatment intensification.

Main Methods:

• A prospective observational study involving 24 PAH patients at the University of Rochester.
• Patients underwent 7-day continuous electrocardiogram monitoring (MC10 Biostamp) at baseline and follow-up.
• Data included rest and sleep heart rate and HRV, with activity periods excluded from analysis.

Main Results:

• No significant differences in heart rate or HRV were found between stable and treatment-intensified PAH groups at baseline or follow-up.
• Changes in heart rate from baseline to follow-up did not differ significantly between the groups.
• Elevated resting and sleep heart rates, but not HRV, predicted 2-year clinical worsening (hospitalization, parenteral therapy, or death).

Conclusions:

• Continuous 7-day home-based HRV monitoring does not appear to enhance PAH assessment compared to functional testing.
• Elevated resting and sleep heart rates are predictive of clinical worsening in PAH.
• Functional testing may be a more effective method for assessing treatment response and clinical risk in PAH.